RESUMEN
The aim of this study was to investigate the expression of integrin linked kinase (ILK) and protein kinase B (PKB/Akt) in acute leukemia (AL), explore the possible effects of ILK/Akt pathway on AL pathogenesis. The expression level of ILK mRNA and Akt mRNA in different types and stages of AL bone marrow mononuclear cells was detected by reverse transcription polymerase chain reaction (RT-PCR). The results showed that the expression of ILK and Akt in do nove AL group was higher than that in AL-CR group and normal control group (P < 0.05), while there was no statistically difference between de nove AL and relapsed AL groups (P > 0.05). The expression of ILK positively correlates with Akt expression in de nove AL group (P < 0.05). It is concluded that the expression of ILK and Akt mRNA is abnormally higher in AL, ILK/Akt pathway may be involved in the pathogenesis and progression of AL and may be a potential therapeutic target for AL.
Asunto(s)
Adolescente , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven , Células de la Médula Ósea , Metabolismo , Leucemia , Metabolismo , Patología , Proteínas Serina-Treonina Quinasas , Metabolismo , Proteínas Proto-Oncogénicas c-akt , Metabolismo , ARN Mensajero , GenéticaRESUMEN
This study was aimed to investigate the expression of SALL4 and BMI-1 mRNA in acute leukemia (AL) and its clinical significance. mRNA expression levels of SALL4 and BMI-1 in 62 AL patients and 10 controls were measured by semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR). The results showed that (1) the expression of SALL4 mRNA were up-regulated in AL (except M3 and T-ALL), and the expression of of SALL4 mRNA in AML was significantly higher than that in B-ALL (p<0.05); expression was negative in 9 out of 10 controls, and expression level of SALL4 mRNA in one case was low; (2) the expression of SALL4 in de novo AL was higher than that in controls, which significantly decreased at complete remission (CR). The difference between CR group and de novo group was statistically significant (p<0.05). In relapsed patients, the expression of SALL4 increased, slightly higher than that in de novo AL group (p>0.05); (3) the expression pattern of BMI-1 was the same to that of SALL4 except the up-regulation in M3, and the expression of BMI-1 was positively correlated with that of SALL4 in acute leukemia (r=0.684, p<0.01). It is concluded that SALL4 and BMI-1 expressions are up-regulated significantly in acute leukemia, which may contribute to the development of leukemia, thus become an important index for evaluation of development, relapse and prognosis in acute leukemia.
Asunto(s)
Adolescente , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven , Estudios de Casos y Controles , Leucemia , Genética , Metabolismo , Leucemia Mieloide Aguda , Genética , Proteínas Nucleares , Genética , Metabolismo , Complejo Represivo Polycomb 1 , Pronóstico , Proteínas Proto-Oncogénicas , Genética , Metabolismo , ARN Mensajero , Genética , Proteínas Represoras , Genética , Metabolismo , Factores de Transcripción , Genética , MetabolismoRESUMEN
To explore the expression of livin gene in acute non-lymphocytic leukemia (ANLL) cells and its clinical significance, the mRNA level of livin gene in 46 ANLL adult patients were measured by using reverse transcription polymerase chain reaction (RT-PCR). Other 10 healthy adults were selected as normal controls (NC), HL-60 cell line was employed as positive control. The results showed that the mRNA level of livin gene in ANLL patients was significantly higher than that in NC, while it decreased in patients with complete remission (CR). In relapsed patients, the level of livin mRNA increased again. In ANLL patients, the CR rate of patients with livin positive was lower than that of patients with livin negative (p<0.05). It is concluded that overexpression of livin gene may play a synergic role in the pathogenesis of ANLL and associates with CR rate in ANLL. It seems that high expression of livin gene may be used as a marker of poor prognosis in acute non-lymphocytic leukemia.